AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $609.96
- 52-wk high
- $647.00
- High
- $615.24
- 52-wk low
- $434.83
- Low
- $606.15
- Prev close
- $603.18
- Mkt cap
- $223.02B
- P/E
- 32.6x
- Volume
- 1.78M
- Fwd P/E
- 22.0x
- Beta
- 0.85
- Div yield
- 0.30%
- P/S
- 4.8x
- P/B
- 4.3x
- Profit margin
- +15.0%
- Op margin
- +18.8%
- ROE
- +13.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 5.6% above what analysts expected.
Earnings per share
$5.71 expected
Revenue
No comparable estimate
Reports Oct 21, 2026, in 39 days
EPS expected
$6.33 to $6.56
Revenue expected
20 analysts
Last 30 days
Analysts raising estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $11.12B | $12.21B | $11.01B | $11.99B |
| Cost of what it sold | $6.47B | $7.58B | $6.53B | $7.05B |
| Gross profit | $4.65B | $4.64B | $4.48B | $4.94B |
| What it spent | ||||
| Research and development | $347.0M | $357.0M | $336.0M | $364.0M |
| Sales and admin | $2.16B | $1.98B | $2.18B | $1.91B |
| Other operating costs | $203.0M | — | $96.0M | $583.0M |
| Total operating expenses | $2.71B | $2.33B | $2.61B | $2.86B |
| What was left | ||||
| Operating profit | $1.94B | $2.30B | $1.86B | $2.09B |
| Interest on debt | $347.0M | $365.0M | $354.0M | $401.0M |
| Profit before tax | $1.83B | $2.12B | $1.73B | $1.92B |
| Tax | $207.0M | $153.0M | $70.0M | $167.0M |
| Net profit | $1.62B | $1.98B | $1.65B | $1.74B |
| EBITDA | $2.84B | $3.21B | $2.31B | $2.57B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Thermo Fisher, Wells Fargo, Nutrien And More On CNBC’s ‘Final Trades’
Leans bullishSep 10Data Aggregation Drives AI's Impact on Clinical Supply Chains
BullishSep 10Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says
BullishSep 9UBS upgrades Thermo Fisher Scientific stock rating on growth outlook
BullishSep 9UBS upgrades Thermo Fisher Scientific stock rating on growth outlook By Investing.com
BullishSep 9Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
Leans bullishSep 9If You Invested $1000 In Thermo Fisher Scientific Stock 15 Years Ago, You Would Have This Much Today
BullishSep 8Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others
Leans bullishSep 8
Macro
30 macro signals shaping TMO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results